• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生物标志物可准确告知局限性前列腺癌的治疗决策。

Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer.

机构信息

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Urology, Singapore General Hospital, Singapore.

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

出版信息

Eur Urol Focus. 2022 May;8(3):643-645. doi: 10.1016/j.euf.2022.03.011. Epub 2022 Mar 23.

DOI:10.1016/j.euf.2022.03.011
PMID:35337775
Abstract

Despite diverse levels of evidence supporting the use of biomarkers at various time points in the management pathway for localised prostate cancer, high-level evidence from prospective head-to-head trials for recommending their routine use to inform treatment decisions is still lacking.

摘要

尽管有不同证据水平支持在局部前列腺癌管理途径的各个时间点使用生物标志物，但仍缺乏前瞻性头对头试验的高级别证据来推荐常规使用这些标志物以告知治疗决策。

相似文献

1
Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer.生物标志物可准确告知局限性前列腺癌的治疗决策。
Eur Urol Focus. 2022 May;8(3):643-645. doi: 10.1016/j.euf.2022.03.011. Epub 2022 Mar 23.
2
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.辅助或早期挽救性放疗治疗局限性和局部进展性前列腺癌：汇总数据的前瞻性计划系统评价和荟萃分析。
Lancet. 2020 Oct 31;396(10260):1422-1431. doi: 10.1016/S0140-6736(20)31952-8. Epub 2020 Sep 28.
3
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research.局限性前列腺癌局灶性消融治疗与标准治疗方案的比较的系统评价：现有证据的局限性及对临床实践和进一步研究的建议
Eur Urol Oncol. 2021 Jun;4(3):405-423. doi: 10.1016/j.euo.2020.12.008. Epub 2021 Jan 8.
4
Cryotherapy for localised prostate cancer.局部前列腺癌的冷冻疗法。
Cochrane Database Syst Rev. 2007 Jul 18(3):CD005010. doi: 10.1002/14651858.CD005010.pub2.
5
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).CDK4/6 抑制剂 LEE011（瑞波西利）在高危局限性前列腺癌中的药效学影响：一项随机对照 II 期试验（LEEP 研究：LEE011 在高危局限性前列腺癌中的应用）研究方案。
BMJ Open. 2020 Jan 26;10(1):e033667. doi: 10.1136/bmjopen-2019-033667.
6
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.局限性前列腺癌中肿瘤缺氧和血管生成的内在标志物与根治性治疗结果：两项随机放疗试验和一项手术队列研究的回顾性分析
Lancet Oncol. 2008 Apr;9(4):342-51. doi: 10.1016/S1470-2045(08)70076-7. Epub 2008 Mar 17.
7
Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.开放手术与机器人辅助腹腔镜根治性前列腺切除术治疗局限性前列腺癌的功能和肿瘤学结局：8 年随访。
Eur Urol. 2021 Nov;80(5):650-660. doi: 10.1016/j.eururo.2021.07.025. Epub 2021 Sep 15.
8
Radical prostatectomy versus watchful waiting for prostate cancer.前列腺癌根治术与观察等待
Cochrane Database Syst Rev. 2010 Nov 10(11):CD006590. doi: 10.1002/14651858.CD006590.pub2.
9
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.用于局限性前列腺癌管理的预后生物标志物：系统评价。
Eur Urol Focus. 2018 Dec;4(6):790-803. doi: 10.1016/j.euf.2017.02.017. Epub 2017 Mar 7.
10
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.局限性前列腺癌的治疗：根据其自然病程（通常进展相对缓慢），可选择观察等待、手术或放射治疗。
Prescrire Int. 2012 Oct;21(131):242-8.

引用本文的文献

1
A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer.一种新型方法能够实现基于新证据的个体风险分层，这有可能在前列腺癌中带来决定性的管理和治疗决策。
Diagnostics (Basel). 2023 Jan 24;13(3):424. doi: 10.3390/diagnostics13030424.
2
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer.前列腺癌根治术前LRG1血水平低可识别出进展为去势抵抗性前列腺癌高风险患者。
Eur Urol Open Sci. 2022 Oct 4;45:68-75. doi: 10.1016/j.euros.2022.09.002. eCollection 2022 Nov.